These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 1978728)
1. Selective 5-hydroxytryptamine2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats. Schmidt CJ; Abbate GM; Black CK; Taylor VL J Pharmacol Exp Ther; 1990 Nov; 255(2):478-83. PubMed ID: 1978728 [TBL] [Abstract][Full Text] [Related]
2. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine. Stone DM; Johnson M; Hanson GR; Gibb JW J Pharmacol Exp Ther; 1988 Oct; 247(1):79-87. PubMed ID: 2902215 [TBL] [Abstract][Full Text] [Related]
3. 5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-dopa. Schmidt CJ; Taylor VL; Abbate GM; Nieduzak TR J Pharmacol Exp Ther; 1991 Jan; 256(1):230-5. PubMed ID: 1899117 [TBL] [Abstract][Full Text] [Related]
4. 3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of [3H]paroxetine-labeled serotonin uptake sites. Battaglia G; Yeh SY; O'Hearn E; Molliver ME; Kuhar MJ; De Souza EB J Pharmacol Exp Ther; 1987 Sep; 242(3):911-6. PubMed ID: 2443644 [TBL] [Abstract][Full Text] [Related]
5. Methylenedioxymethamphetamine-induced hyperthermia and neurotoxicity are independently mediated by 5-HT2 receptors. Schmidt CJ; Black CK; Abbate GM; Taylor VL Brain Res; 1990 Oct; 529(1-2):85-90. PubMed ID: 1980848 [TBL] [Abstract][Full Text] [Related]
6. Blockade of striatal 5-hydroxytryptamine2 receptors reduces the increase in extracellular concentrations of dopamine produced by the amphetamine analogue 3,4-methylenedioxymethamphetamine. Schmidt CJ; Sullivan CK; Fadayel GM J Neurochem; 1994 Apr; 62(4):1382-9. PubMed ID: 7907650 [TBL] [Abstract][Full Text] [Related]
7. The 5-HT2 receptor antagonist, MDL 28,133A, disrupts the serotonergic-dopaminergic interaction mediating the neurochemical effects of 3,4-methylenedioxymethamphetamine. Schmidt CJ; Black CK; Taylor VL; Fadayel GM; Humphreys TM; Nieduzak TR; Sorensen SM Eur J Pharmacol; 1992 Sep; 220(2-3):151-9. PubMed ID: 1425989 [TBL] [Abstract][Full Text] [Related]
8. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine. Schmidt CJ J Pharmacol Exp Ther; 1987 Jan; 240(1):1-7. PubMed ID: 2433425 [TBL] [Abstract][Full Text] [Related]
9. Effects of 3,4-methylenedioxyamphetamine and 3,4-methylenedioxymethamphetamine isomers on central serotonergic, dopaminergic and nigral neurotensin systems of the rat. Johnson M; Letter AA; Merchant K; Hanson GR; Gibb JW J Pharmacol Exp Ther; 1988 Mar; 244(3):977-82. PubMed ID: 2472482 [TBL] [Abstract][Full Text] [Related]
10. Elevation of serum prolactin and corticosterone concentrations in the rat after the administration of 3,4-methylenedioxymethamphetamine. Nash JF; Meltzer HY; Gudelsky GA J Pharmacol Exp Ther; 1988 Jun; 245(3):873-9. PubMed ID: 2898523 [TBL] [Abstract][Full Text] [Related]
11. The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats. Mechan AO; Esteban B; O'Shea E; Elliott JM; Colado MI; Green AR Br J Pharmacol; 2002 Jan; 135(1):170-80. PubMed ID: 11786492 [TBL] [Abstract][Full Text] [Related]
12. Effect of flunarizine and nimodipine on the decrease in tryptophan hydroxylase activity induced by methamphetamine and 3,4-methylenedioxymethamphetamine. Johnson M; Mitros K; Stone DM; Zobrist R; Hanson GR; Gibb JW J Pharmacol Exp Ther; 1992 May; 261(2):586-91. PubMed ID: 1374469 [TBL] [Abstract][Full Text] [Related]
13. Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. Callaway CW; Wing LL; Geyer MA J Pharmacol Exp Ther; 1990 Aug; 254(2):456-64. PubMed ID: 1974635 [TBL] [Abstract][Full Text] [Related]
14. Role of the 5-HT2 receptor in the methamphetamine-induced neurochemical alterations. Johnson M; Sonsalla PK; Letter AA; Hanson GR; Gibb JW J Pharmacol Exp Ther; 1994 Jul; 270(1):97-103. PubMed ID: 7913500 [TBL] [Abstract][Full Text] [Related]
15. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. Commins DL; Vosmer G; Virus RM; Woolverton WL; Schuster CR; Seiden LS J Pharmacol Exp Ther; 1987 Apr; 241(1):338-45. PubMed ID: 2883295 [TBL] [Abstract][Full Text] [Related]
16. Antagonism of the neurotoxicity due to a single administration of methylenedioxymethamphetamine. Schmidt CJ; Black CK; Taylor VL Eur J Pharmacol; 1990 May; 181(1-2):59-70. PubMed ID: 1974858 [TBL] [Abstract][Full Text] [Related]
17. The effects of amphetamine-like designer drugs on monoaminergic systems in rat brain. Gibb JW; Stone DM; Stahl DC; Hanson GR NIDA Res Monogr; 1987; 76():316-21. PubMed ID: 2449619 [TBL] [Abstract][Full Text] [Related]
18. Effect of repeated ('binge') dosing of MDMA to rats housed at normal and high temperature on neurotoxic damage to cerebral 5-HT and dopamine neurones. Sanchez V; O'shea E; Saadat KS; Elliott JM; Colado MI; Green AR J Psychopharmacol; 2004 Sep; 18(3):412-6. PubMed ID: 15358986 [TBL] [Abstract][Full Text] [Related]
19. Increased CRE-binding activity and tryptophan hydroxylase mRNA expression induced by 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") in the rat frontal cortex but not in the hippocampus. García-Osta A; Del Río J; Frechilla D Brain Res Mol Brain Res; 2004 Jul; 126(2):181-7. PubMed ID: 15249142 [TBL] [Abstract][Full Text] [Related]
20. Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT. Shankaran M; Yamamoto BK; Gudelsky GA Synapse; 2001 Apr; 40(1):55-64. PubMed ID: 11170222 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]